繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNS01

SNS01

Indication
Cancer
Ingredient
Human antibody
Product Advantages
Most of traditional anti-cancer drugs could not specifically target cancer cells because of the tumor mass usually composed of organized and heterogenetic types of cancer-associated cells. Cancer stem cells and tumor microenvironment play important roles on drug resistance, relapse and metastasis, which caused it difficult to treatment.
Status
Pre-clinical
Mechanism
Through suppress cancer stem cell proliferation and block cell renew ability, also can suppress the cytokine secretion from cancer stem cells. This could destroy the tumor microenvironment, therefore suppresses the surrounding tumor growth.
Potential Market
The recurrent non-small cell lung cancer (NSCLC) patients only can be treated with a few drugs which market value is $ 5.6 billion.
  • By the Company’s exclusive authorization from NTU, which identified CDX as the novel Lung cancer stem cells (LCSCs) markers, it also been identified can functionally promote the cancer stemness. Through anti-cancer stem cell drug platform screening, we identified SNS01 which target CDX.
  • As an anti-cancer stem cell drug, SNS01 not only could suppress tumorous sphere formation and self-renewing, but also suppresses cytokine secreted from CSCs. In addition, CDX could regulate the expression of immune checkpoint PD-L1, which enable it to be combine with immune checkpoint inhibitors. The combination of SNS01 with immune checkpoint inhibitors (ICIs) may increase the response rate to ICIs by activating T cells, thus improve the caner treatment therapy.
  • SNS01 will focus on target late- stage cancer, aims to prevent cancer recurrence and metastasis. Under this primes, it would get the license of Breakthrough Therapy Designation,BTD for FDA.


体彩p5中奖新闻 江西快3开奖号码分布图 理财规划师 创业板股票涨跌幅 上海快三遗漏数据查询 疯狂赛车游戏下载安装 贵州11选5前三组走试图 股票涨跌西部证券 有河南快三的网投 四川福彩快乐12遗漏表 重庆时时开奖直播视频